Shire to resume marketing of Adderall XR

Share this article:

Shire Pharmaceuticals said that Canadian regulators have approved the company's request to resume marketing Adderall XR in that country.
Health Canada suspended sales of Adderall XR, Shire's biggest product, in February amid concerns the ADHD drug could cause sudden death in some patients. Shire quickly appealed the decision.
The regulatory agency reversed its decision on the advice of its New Drug Committee, which conducted a review of Adderall, Shire said.
With global sales of $607 million last year, Adderall accounts for more than half of Shire's total sales and profit.
Following Canada's withdrawal of Adderall XR, the U.S. FDA worked with Shire to add a warning to the drug's label not to use it in children or adults with heart defects.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.